Comparative Pharmacology
Head-to-head clinical analysis: AUVI Q versus EPIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUVI Q versus EPIPEN.
AUVI-Q vs EPIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic stimulation increases peripheral vascular resistance, reversing hypotension and improving coronary perfusion. Beta-adrenergic stimulation causes bronchodilation, positive chronotropic and inotropic effects, and vasodilation.
Nonselective alpha-1, alpha-2, beta-1, beta-2, beta-3 adrenergic receptor agonist; causes vasoconstriction (alpha-1), bronchodilation (beta-2), and increased cardiac contractility and heart rate (beta-1).
0.3 mg intramuscularly into anterolateral thigh, repeated every 5-15 minutes as needed.
0.3 mg intramuscularly (lateral thigh) every 5-15 minutes as needed for anaphylaxis.
None Documented
None Documented
The terminal elimination half-life of epinephrine is approximately 2–3 minutes when administered intravenously. After intramuscular injection, the half-life is extended to about 20–30 minutes due to slower absorption, providing a longer duration of therapeutic effect.
2-3 minutes (IV); clinical context: ultra-short half-life necessitates repeated doses or continuous infusion for sustained effect
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Renal excretion of metabolites accounts for the majority of elimination; less than 5% is excreted unchanged in urine.
Renal (90% as metabolites, 10% unchanged); biliary/fecal (<5%)
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist